ProMIS Neurosciences (PMN) Non Operating Income (2021 - 2025)
ProMIS Neurosciences' (PMN) quarterly Non Operating Income came in at $98031.0 in Q4 2025, down 98.3% YoY from $5.8 million in Q4 2024, and down 42.44% on a QoQ basis from $170306.0 in Q3 2025.
ProMIS Neurosciences (PMN) Non Operating Income (2021 - 2025) Analysis & Trends
ProMIS Neurosciences (PMN) has 5 years of Non Operating Income data on file, last reported at $98031.0 in Q4 2025.
- Quarterly Non Operating Income fell 98.3% year-over-year to $98031.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $448161.0 (down 97.71% YoY) and the FY2025 annual result came in at $448161.0, down 97.71% from the prior year.
- Non Operating Income declined to $98031.0 in Q4 2025, from $170306.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $13.7 million in Q3 2024 to a low of $11240.0 in Q1 2023.
- A 5-year average of $1.6 million and a median of $294208.0 in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income slumped 99.39% — and 2024, when it soared 8638.82%.
- Tracing PMN's Non Operating Income over 5 years: stood at $2.3 million in 2021, then plunged by 45.4% to $1.3 million in 2022, then plunged by 76.6% to $294208.0 in 2023, then jumped by 1859.24% to $5.8 million in 2024, then sank by 98.3% to $98031.0 in 2025.
- The last three Non Operating Income figures came in at $98031.0 (Q4 2025), $170306.0 (Q3 2025), and $67632.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 98,031.00 |
| Sep 30, 2025 | 170,306.00 |
| Jun 30, 2025 | 67,632.00 |
| Mar 31, 2025 | 112,192.00 |
| Dec 31, 2024 | 5.76 Mn |
| Sep 30, 2024 | 13.71 Mn |
| Jun 30, 2024 | 90,049.00 |
| Mar 31, 2024 | 41,563.00 |
| Dec 31, 2023 | 294,208.00 |
| Sep 30, 2023 | 156,892.00 |
| Jun 30, 2023 | 587,910.00 |
| Mar 31, 2023 | 11,240.00 |
| Dec 31, 2022 | 1.26 Mn |
| Sep 30, 2022 | 97,260.00 |
| Jun 30, 2022 | 2.12 Mn |
| Mar 31, 2022 | 1.84 Mn |
| Dec 31, 2021 | 2.30 Mn |
| Sep 30, 2021 | 860,235.00 |
| Jun 30, 2021 | 879,873.00 |